Printer Friendly

WYETH-AYERST LABORATORIES SUPPORTS THE AMERICAN HEART ASSOCIATION'S STATEMENT ON CARDIOVASCULAR DISEASE IN WOMEN

 PHILADELPHIA, Oct. 11 /PRNewswire/ -- Wyeth-Ayerst Laboratories, the world leader in women's health care, today expressed strong support for the American Heart Association's (AHA) call for action to prevent cardiovascular disease in women.
 The call for action was made in a special report, "Cardiovascular Disease in Women," published in the October issue of Circulation, the official journal of the AHA.
 As the report states, cardiovascular diseases are the leading causes of death in women in the United States, claiming more lives than cancer, accidents and diabetes combined. Each year, more than 236,000 women die of a heart attack and more than 87,000 die of a stroke. "Cardiovascular risk is an extremely vital issue for American women and we applaud this important step by the AHA to focus renewed attention on it," said Robert Essner, president of Wyeth-Ayerst Laboratories.
 The AHA report discusses risk factors for cardiovascular diseases, including estrogen deficiency in post-menopausal women and issues related to diagnosis, treatment, prognosis and rehabilitation of women with coronary heart disease. In its discussion of oral contraceptives, the paper recognizes that, while higher dose oral contraceptives of the 1960s and 70s were associated with increased risk of cardiovascular events while on treatment, today's commonly prescribed low-dose oral contraceptives carry substantially less risk.
 "As the world leader in hormone therapy for all stages of a woman's life," said Essner, "Wyeth-Ayerst Laboratories endorses the AHA in this effort to better inform health care providers and the public at large about prevention of cardiovascular disease in women." Wyeth-Ayerst is currently funding a $40 million nationwide study call HERS, The Heart and Estrogen-Progestin Replacement Study, to determine the impact of estrogen replacement therapy in post-menopausal women.
 Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE: AHP), is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines and infant nutritionals. American Home Products Corporation is one of the world leaders in prescription drugs, packaged medicines, medical supplies, instrumentation and food.
 /delval/
 -0- 10/11/93
 /CONTACT: Audrey Ashby of Wyeth-Ayerst Laboratories, 215-971-5823/
 (AHP)


CO: Wyeth-Ayerst Laboratories; American Home Products Corporation;
 American Heart Association ST: Pennsylvania IN: MTC SU:


MP-MK -- PH005 -- 0578 10/11/93 09:38 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 11, 1993
Words:379
Previous Article:STEEL RECYCLING INSTITUTE APPOINTS BEN WALKER SOUTHWESTERN REGION RECYCLING MANAGER; GARY GALLO MOVES TO CENTRAL EASTERN REGION
Next Article:SUNOCO'S CAR SCRAPPAGE PROGRAM GENERATES 'TREMENDOUS' RESPONSE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters